Journal of Commercial Biotechnology - Table 1 for article: Cloning an industry: Strategy typologies of Shanghai biotechnology companies

FROM:

Cloning an industry: Strategy typologies of Shanghai biotechnology companies

Ken Malone, Brent Hales, Justin Chan, Monica Love and Jeremiah Rayner

Company designation	Start-up year	2006 sales (000 RMB)	Number of employees	Current business model *	Primary sales region **
A	1994	Pre-revenue	<20	Mfg and sales of products to businesses	Global
B	2000	Pre-revenue	40	Mfg and sales of products through MDs	China
C	2001	Pre-revenue	9	Mfg and sales of intermediates to businesses	China
D	2002	Pre-revenue	30	Selling R&D services	China
E	2002	Pre-revenue	5	Mfg and sales of products through MDs	China
F	2003	Pre-revenue	30	Sell IP to big Pharma and/or be acquired	China
G	2003	Pre-revenue	10	Selling R&D services	China
H	2005	Pre-revenue	9	Mfg and sales of intermediates to businesses	Global
I	1992	75,000	200	Mfg and sales of products through MDs	China
J	1993	5,500,000	150	Mfg and sales of intermediates to businesses	Global
K	1996	50	54	Mfg and sales of products through MDs	China
L	1996	1,095,000	2,500	Mfg and sales of products through MDs	N America
M	1998	10,000	400	Mfg and sales of intermediates to businesses	Global
N	2001	2,000	<100	Mfg and sales of products through MDs	China
O	2001	8,000	150	Mfg and sales of products through MDs	China
P	2001	?	90	Mfg and sales of intermediates to businesses	China
Q	2002	?	45	Mfg and sales of products through MDs	China
R	2004	900	11	Mfg and sales of intermediates to businesses	Global
S	2004	<1,000	11	Sales of products to businesses	Global

* For pre-revenue businesses, this is their intended model. For businesses with existing sales, this is the model for their on-going business.

** For pre-revenue businesses, this is their intended sales region. For businesses with existing sales, this is their current sales region.